×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: diabetes | drug | Type 2 | Xultophy

New Diabetes Drug OK'd

New Diabetes Drug OK'd

(Copyright DPC)

Tuesday, 22 November 2016 08:17 AM

Novo Nordisk A/S said the U.S. Food and Drug Administration approved on Monday its diabetes drug, Xultophy.

The Danish drug maker said it planned to launch the drug in the United States in the first half of 2017.

Xultophy, approved in Europe since 2014, combines Novo's drug Tresiba, known also as insulin degludec, with its GLP-1 agonist Victoza, known also as liraglutide.

The drug, given by once-daily injection, aims to improve glycemic control in adults with type 2 diabetes.

There are nearly 400 million people worldwide suffering from diabetes, with type 2 accounting for more than 90 percent.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
Novo Nordisk A/S said the U.S. Food and Drug Administration approved on Monday its diabetes drug, Xultophy.The Danish drug maker said it planned to launch the drug in the United States in the first half of 2017.Xultophy, approved in Europe since 2014, combines Novo's drug...
diabetes, drug, Type 2, Xultophy
98
2016-17-22
Tuesday, 22 November 2016 08:17 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved